Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

The vBlocT2D Study

25. april 2019 opdateret af: Kaiser Permanente

vBloc Therapy for Obese Subjects With Type 2 Diabetes- A Randomized Controlled Clinical Trial

Overall aim: To demonstrate that weight loss through vBloc Therapy in combination with usual care will achieve better glycemic control for patients with obesity and type 2 diabetes than usual care alone.

Duration: Participants will be asked to participate in a 12 month study that involves a baseline visit and research follow-up visits at 3, 6, 9, and 12 months.

Sample Size: 60 participants will be enrolled in the study. Of these, 30 will be randomized to vBloc therapy and 30 will be randomized to usual care.

Studieoversigt

Status

Trukket tilbage

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The vBlocT2D study is a two arm, randomized, controlled, unblinded clinical trial in which 60 adult patients with T2D with moderate to extreme obesity (BMI 35-45 kg/m2) and suboptimal glycemic control (glycated haemoglobin (HbA1c) 7-10%) without significant diabetic complications, will be randomized to usual care alone (n=30) or vBloc therapy plus usual care (n=30) to assess the superiority of vBloc therapy plus usual care than standard usual care alone in improving diabetic control. The vBloc therapy will be delivered through an electrical and reversible vagal blocking device (the Maestro Rechargeable System) implanted using laparoscopic surgery. The device was approved by the FDA in 2015 for weight loss in adults with BMI 40-45 kg/m2, or BMI 35-39.9 kg/m2 with one or more obesity-related co-morbid conditions. The study will recruit patients over a 12-month period and follow each individual for 12-months post intervention. The primary outcome is change in HbA1c at 12-months post randomization. The secondary outcomes are changes in weight, waist and hip circumferences, blood pressure, lipids, insulin sensitivity and β-cell health measured through oral glucose tolerance testing, dietary intake, eating behaviors, physical activity, quality of life and potential circulating biomarkers. Medication use, clinical labs and adverse events will be compared as well.

Undersøgelsestype

Interventionel

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Harbor City, California, Forenede Stater, 90710
        • Kaiser Permanente South Bay Medical center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Type 2 diabetes with HbA1c level 7-10% inclusive, AND known duration of disease ≤10 years, AND
  2. Male or female (females of child-birth potential not pregnant at implant or for duration of study), AND
  3. Age 18 years or older, AND
  4. Body mass index (BMI) 35-45 kg/m2 inclusive, AND
  5. Attempt and failed diet, exercise and behavioral modification program within past five years,

Exclusion Criteria:

  1. Use of GLP-1 receptor agonists for diabetes currently or within past 6 months
  2. Contraindications to vBloc (permanently implanted, electrical-powered medical device or gastrointestinal device or prosthesis (e.g. pacemakers, implanted defibrillators, neurostimulators))
  3. Patients for whom magnetic resonance imaging (MRI), shortwave, microwave, or therapeutic ultrasound diathermy is planned (Note: Diathermy is any treatment that uses high-frequency electromagnetic radiation, electric currents, or ultrasonic waves to produce heat in body tissues. Patients absolutely CANNOT be treated with any type of shortwave, microwave, or therapeutic ultrasound diathermy device whether or not it is used to produce heat. These treatments should not be applied anywhere on the body)
  4. Underlying disease(s) likely to (a) limit life span to less than study duration and/or (b) increase risk of intervention outside of the study and/or (c) limit ability to participate in outcomes assessment and/or (d) limit participation
  5. Previous bariatric or upper GI surgery
  6. Excessive alcohol intake
  7. Current smokers or smoking cessation in prior 3 months
  8. An underlying disease known to have important effects on glucose metabolism
  9. Active infections
  10. Anemia (Hemoglobin <11g/dl in women, <12 g/dl in men) or known coagulopathy
  11. Chronic kidney disease manifest as serum creatinine >2.0 mg/dl
  12. Diabetic retinopathy requiring photocoagulation therapy
  13. Symptomatic diabetic gastroparesis
  14. Cardiovascular disease, including uncontrolled hypertension and symptomatic congestive heart failure
  15. Cirrhosis of the liver, portal hypertension, or esophageal varices
  16. Symptomatic esophageal reflux
  17. Conditions or behaviors likely to affect the conduct of the vBloc Study

    1. Unable or unwilling to give informed consent
    2. Unable to adequately communicate with clinic staff
    3. Current or anticipated participation in another intervention research project that would interfere with any of the interventions/outcomes in vBloc study
    4. Likely to move away from participating clinic in next 2 years
    5. Current (or anticipated) pregnancy and lactation.
    6. Major psychiatric disorder that, in the opinion of investigators, would impede participation in the study
    7. Weight loss >7% in past two months for any reason except postpartum weight loss.
  18. Additional conditions may serve as criteria for exclusion at the discretion of the study investigators.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: vBloc Therapy + Usual Care for Type 2 Diabetes
The vBloc device will be placed using a laparoscopic procedure. The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. . Pre-operative testing will be conducted per surgeon's evaluation. Participants will receive weight management education according to the vBloc Therapy protocol.
Ingen indgriben: Usual Care for Type 2 Diabetes

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Mean reduction in HbA1c
Tidsramme: at 12 months after baseline
at 12 months after baseline

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Anny Xiang, PhD, Kaiser Permanente

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

23. februar 2018

Primær færdiggørelse (Faktiske)

30. november 2018

Studieafslutning (Faktiske)

30. november 2018

Datoer for studieregistrering

Først indsendt

22. november 2017

Først indsendt, der opfyldte QC-kriterier

22. november 2017

Først opslået (Faktiske)

28. november 2017

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. april 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. april 2019

Sidst verificeret

1. april 2019

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • KPSC IRB 11343 (Anden identifikator: Kaiser Permanente Southern California IRB)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med vBloc Therapy

Abonner